Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Medical
- Cancer
- Delivery
- Therapeutic
- Device
- Supply
- Radiation
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 908
License Grant
Licensor hereby grants Licensee, for the option premium stated above, an exclusive option to investigate Licensor 's invention for the term indicated above, such term to commence from the date of this Agreement. Licensor will furnish Licensee with all information and know-how (if any) concerning Licensor 's invention in Licensor 's possession.
License Property
Licensor has developed an invention titled 'Method for manufacturing and using Cs-131 seeds for radiotherapy' .
Field of Use
Brachytherapy seeds are small devices that deliver therapeutic radiation directly to tumors. Each seed contains a radioisotope sealed within a welded titanium case. In prostate cancer procedures, approximately 85 to 135 seeds are permanently implanted in a 45-minute outpatient procedure. The isotope decays over time, and the seeds become inert. The seeds may be used as a primary treatment or in conjunction with other treatment modalities such as external beam radiation therapy, chemotherapy, or as treatment for residual disease after excision of primary tumors.
IPSCIO Record ID: 26657
License Grant
Licensor, an individual, hereby further sells, assigns, transfers, and sets over unto Licensee, entire right, title and interest in and to said invention in each and every country foreign to the United States; and Licensor further conveys to Licensee all of all priority rights resulting from the above-identified application for United States patent.
License Property
The application for United States patent therefore, signed by Licensor on 04/28/99, U.S. Patent and Trademark Office Application Number 09/301,640, filed 04/28/99 entitled Method of Separation of Cesium-131 from Barium.
Patent #6,066,302 for applications including but not limited to cancer research and treatment.
The process was developed by a shareholder of the Company, and has been assigned Exclusively to the Company. A patent for the Cesium separation and purification process.
Field of Use
The rights granted apply to the healthcare industry.
IPSCIO Record ID: 1370
License Grant
The Company acquired exclusive worldwide rights to the GliaSite® Radiation Therapy System.
Licensor is willing to grant Licensee rights to the Licensor IP in the Territory with a limited field of use of intracavity radiation therapy (brachytherapy) of the brain (“Exclusive Field of Useâ€).
License Property
the GliaSite® Radiation Therapy System, the only FDA-cleared balloon catheter device used in the treatment of brain cancer.
GliaSite® Radiation Therapy System (RTS) is for the treatment of brain cancer, i.e. primary and recurrent gliomas and metastic brain tumors. Specifically, the intended use of GliaSite® RTS is the management of surgically resectable brain tumors where adjuvant radiation therapy of the post-resection tissue bed is indicated.
IPSCIO Record ID: 264174
License Grant
The Company has agreed to revised terms regarding the license fee and to increase the royalty fee on net sales as regards to the use of its patented RadioGelâ„¢ technology from a private nonprofit applied science and technology development company.
License Property
RadioGelâ„¢ is an injectable particle-gel, for brachytherapy radiation treatment of cancerous tumors in people and animals.
RadioGelâ„¢ is a brachytherapy device comprising highly insoluble Yttrium-90 particles delivered by needle injection using a water-polymer composite for high-dose treatment of non-resectable solid tumors that cannot be treated effectively by any other means. It is designed for maximum safety to deliver a high, pure-beta radiation dose to target (tumor) tissue, with comparatively small-to-negligible radiation doses to adjacent normal tissues, and with negligible radiation dose to any major organ or tissue in the body.
RadioGelâ„¢ is comprised of a hydrogel, or a substance that is liquid at room temperature and then gels when reaching body temperature after injection into a tumor. In the gel are small, one micron, yttrium-90 phosphate particles (“Y-90â€). Once injected, these inert particles are locked in place inside the tumor by the gel, delivering a very high local radiation dose. The radiation is beta, consisting of high-speed electrons. These electrons only travel a short distance so the device can deliver high radiation to the tumor with minimal dose to the surrounding tissue. Optimally, patients can go home immediately following treatment without the risk of radiation exposure to family members. Since Y-90 has a half-life of 2.7 days, the radioactively drops to 5% of its original value after ten days.
Field of Use
This agreement pertains to the medical industry relating to a radiation oncology medical device for the development of the yttrium-90 based brachytherapy device RadioGelâ„¢ for the treatment of non-resectable tumors.
IPSCIO Record ID: 286475
License Grant
The Institute, a private nonprofit applied science and technology development company, has granted the Company an exclusive license to patents covering the manufacturing, processing and applications of RadioGelâ„¢.
As a result of this Amendment, the Company has agreed to revised terms regarding the license fee and royalty rate.
License Property
RadioGelâ„¢ is comprised of a hydrogel, or a substance that is liquid at room temperature and then gels when reaching body temperature after injection into a tumor. In the gel are small, one micron, yttrium-90 phosphate particles (“Y-90â€). Once injected, these inert particles are locked in place inside the tumor by the gel, delivering a very high local radiation dose. The radiation is beta, consisting of high-speed electrons. These electrons only travel a short distance so the device can deliver high radiation to the tumor with minimal dose to the surrounding tissue. Optimally, patients can go home immediately following treatment without the risk of radiation exposure to family members. Since Y-90 has a half-life of 2.7 days, the radioactively drops to 5% of its original value after ten days.
Field of Use
RadioGelâ„¢ is a brachytherapy device comprising highly insoluble Yttrium-90 particles delivered by needle injection using a water-polymer composite for high-dose treatment of non-resectable solid tumors that cannot be treated effectively by any other means. It is designed for maximum safety to deliver a high, pure-beta radiation dose to target (tumor) tissue, with comparatively small-to-negligible radiation doses to adjacent normal tissues, and with negligible radiation dose to any major organ or tissue in the body.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
